News Releases | Portage Biotech

Year

25 Apr '22

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines Portage and NCI will develop agents to enhance the efficacy of proprietary cancer vaccines and mouse model cancer vaccines developed by the NCI WESTPORT, Conn.

13 Apr '22

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Late-breaking preclinical data generated by Stimunity suggests that packaging cGAMP STING activator in a virus-like particle leads to activation of tumor-specific T cells WESTPORT, Conn. , April 13, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. , (NASDAQ: PRTG) (“Portage” or the “Company”), a

31 Mar '22

Portage Biotech Provides Update on Clinical-Stage and Development Programs

Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development Company continues to work toward multiple clinical readouts in 2022 Portage is accelerating studies by expanding regions and clinical sites; continued advancement of pipeline

09 Mar '22

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

Preclinical data will be presented in a late-breaking abstract session WESTPORT, Conn. , March 09, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival

24 Feb '22

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

Company working to accelerate lead clinical programs; expects multiple clinical readouts in 2022 WESTPORT, Conn. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient

15 Feb '22

Portage Biotech Announces New Appointments to its Management Team and Board of Directors

Leading biopharma executive Brian Wiley joins as Chief Business Officer Experienced financial consultant Joseph Ciaverella advances to new role as Chief Accounting Officer Jim Mellon , Linda Kozick and Mark Simon will join Portage’s Board of Directors WESTPORT, Conn. , Feb.

05 Jan '22

Portage Biotech Announces Participation in January 2022 Investor Conferences

WESTPORT, Conn. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced